Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey.

CONCLUSIONS: The present statements aim to fill current gaps in treatment guidelines by providing recommendations based on expert consensus in clinical settings in which patients progress following first-line therapy with octreotide LAR. PMID: 32990061 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32990061?dopt=Abstract

Source: Expert Opinion on Pharmacotherapy - September 30, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research